AKESO News

AKESO: Notification Letter and Reply Form to Non-registered Holders - Notice of Publication of 2023 Annual Report

Apr 29 22:41

AKESO: Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of 2023 Annual Report

Apr 29 22:39

AKESO: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Apr 29 22:35

AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER

Apr 24 08:15

AKESO: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Apr 8 16:37

AKESO: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Apr 8 16:34

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024

Apr 5 17:11

AKESO: Next Day Disclosure Return

Mar 28 20:43

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024

Mar 5 18:06

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024

Feb 6 18:13

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023

Jan 5 17:21

AKESO: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR GASTRIC CANCER

Jan 5 08:22

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2023

Dec 6, 2023 17:45

AKESO: VOLUNTARY ANNOUNCEMENT - AK104-303, A PHASE III TRIAL OF CADONILIMAB REACHED PROGRESSION-FREE-SURVIVAL (PFS) PRIMARY ENDPOINT AT INTERIM ANALYSIS FOR FIRST LINE TREATMENT OF CERVICAL CANCER

Nov 23, 2023 07:00

AKESO: VOLUNTARY ANNOUNCEMENT - AK104-302, A PHASE III TRIAL OF CADONILIMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST LINE TREATMENT FOR GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJC) REACHED PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AT INT

Nov 7, 2023 07:00

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2023

Nov 6, 2023 17:09

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2023

Oct 6, 2023 17:00

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2023

Sep 5, 2023 17:17

AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR THE EBDAROKIMAB INJECTION (IL-12/IL-23 MONOCLONAL ANTIBODY, AK101) INDEPENDENTLY-DEVELOPED BY AKESO

Aug 24, 2023 08:29

AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2023

Aug 2, 2023 17:19